# A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

> **NCT05951608** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Akeso** · enrollment: 216 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** AK127 in combination with AK112

## Key facts

- **NCT ID:** NCT05951608
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-16
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-08-15
- **Target enrollment:** 216 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05951608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05951608, "A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05951608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*